Research programme: cancer and sepsis therapeutics - TaiRx

Drug Profile

Research programme: cancer and sepsis therapeutics - TaiRx

Alternative Names: EFP 306; Rexis; TRX 306; TRX 606

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator TaiRx
  • Class Anti-infectives; Antineoplastics
  • Mechanism of Action Growth inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Sepsis

Most Recent Events

  • 29 Jul 2015 Preclinical trials in Sepsis (Adjunctive treatment) in Taiwan before July 2015 (unspecified route)
  • 29 Jul 2015 Preclinical trials in Cancer in Taiwan before July 2015 (PO)
  • 29 Jul 2015 TaiRx files IND application for TRX 306 for Sepsis in Taiwan, before June 2015 (TaiRx website, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top